Vivimed Labs Ltd will resume trading on BSE and NSE from December 18, 2025, after suspension was revoked. The halt, imposed in January 2023 due to SEBI compliance lapses, has now been resolved. Trading will restart under the T group, restoring liquidity and investor confidence in the company.
Vivimed Labs Ltd has received a major boost as both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) have officially revoked the suspension of trading in its equity shares, effective December 18, 2025. This marks a significant turnaround for the pharmaceutical and specialty chemicals company, which had faced suspension due to non-compliance with SEBI’s Listing Obligations and Disclosure Requirements (LODR) regulations.
Key highlights from the announcement:
-
Trading Resumption: Shares of Vivimed Labs will resume trading under the Trade-for-Trade segment in the T group, reinstating liquidity for investors.
-
Reason for Suspension: Trading was halted in January 2023 due to non-compliance with Regulation 34 of SEBI (LODR) for FY21 and FY22.
-
Compliance Achieved: The company has now addressed regulatory lapses, enabling the exchanges to lift the suspension.
-
Investor Impact: The revocation restores price discovery and market participation, offering relief to shareholders after nearly three years.
-
Future Outlook: The move signals Vivimed’s renewed commitment to transparency and compliance, potentially improving investor confidence in its long-term growth trajectory.
This development is expected to re-energize Vivimed’s market presence, allowing stakeholders to re-engage with the company’s equity story.
Sources: ScanX News, NSE Circular, BSE Notice